Home | Lymphoma Hub

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Steering Committee About Us Newsletter Contact

Visit:

Steering Committee About Us Newsletter Contact

Subtypes Therapeutics Congresses Trials Expert Opinions

EBMT 2020

Lymphoma & CLL Subtypes

A retrospective study of the clinical and pathological features of peripheral T-cell lymphomas in a Spanish population

Subclassifying T-cell lymphomas (TCLs) is difficult due to the heterogeneity and broad morphological spectrum of this group of...

Aug 11, 2020

| PTCL

IRC recommends to focus on one dosage arm to complete the PARADIGME phase IIb trial

On August 6, 2020, after a planned interim analysis of the PARADIGME phase IIb trial, the Independent Review Committee (IRC) recommended to focus on one dosage arm to...

Aug 7, 2020

| FL

Phase II study of tisagenlecleucel in patients with R/R FL meets its primary endpoint

On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating tisagenlecleucel in patients with relapsed or...

Aug 4, 2020

| FL

FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL

On July 31, 2020, the U.S. Food and Drug Administration (FDA) approved tafasitamab in combination with lenalidomide as second-line...

Aug 4, 2020

Gilles Salles

" The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology. "

Featured Expert Opinion

Practice-changing abstracts in indolent lymphoma at EHA 2020

Interview with Martin Dreyling outlining the practice-changing abstracts in indolent lymphoma from EHA 2020.

Diffuse large B-cell lymphoma

FDA approves tafasitamab in combination with lenalidomide as second-line treatment for patients with R/R DLBCL

On July 31, 2020, the U.S. Food and Drug Administration (FDA) approved tafasitamab in...

Aug 4, 2020

| DLBCL

Results from phase I ALEXANDER study investigating the first CAR T-cell therapy, AUTO3, plus pembrolizumab to target both CD19 and CD22 in the treatment of R/R DLBCL

Available CD19 chimeric antigen...

Jul 31, 2020

| ASCO 2020

Lisocabtagene maraleucel as a second-line treatment | Interim results of phase II PILOT trial

The ongoing, open-label phase II PILOT trial (NCT03483103) is the first study to assess the efficacy and...

Jul 22, 2020

| ASCO 2020

EMA validates marketing authorization application for lisocabtagene maraleucel for the treatment of adults with B-cell non-Hodgkin lymphoma

On July 17, 2020, the European Medicines Agency (EMA)...

Jul 21, 2020

Mature T and NK cell neoplasms

A retrospective study of the clinical and pathological features of peripheral T-cell lymphomas in a Spanish population

Subclassifying T-cell lymphomas (TCLs) is difficult due to the heterogeneity and...

Aug 11, 2020

| PTCL

FDA grants orphan drug designation to cobomarsen, for the treatment of T-cell lymphoma

On July 23, 2020, the U.S. Food & Drug Administration (FDA) granted orphan drug designation to cobomarsen...

Jul 24, 2020

| CTCL

Interim data from the phase I/II study on BNZ-1 in patients with refractory cutaneous T-cell lymphoma

On July 20, 2020, positive interim clinical data from the phase I/II study of BNZ-1 in patients...

Jul 24, 2020

| CTCL

NICE recommends brentuximab vedotin in combination with chemotherapy as frontline treatment for systemic anaplastic large cell lymphoma

The National Institute for Health and Care Excellence (NICE)...

Jul 13, 2020

| ALCL

Follicular lymphoma

IRC recommends to focus on one dosage arm to complete the PARADIGME phase IIb trial

On August 6, 2020, after a planned interim analysis of the PARADIGME phase IIb trial, the Independent Review...

Aug 7, 2020

| FL

Phase II study of tisagenlecleucel in patients with R/R FL meets its primary endpoint

On August 4, 2020, positive results were announced from the phase II ELARA trial (NCT03568461), investigating...

Aug 4, 2020

| FL

Lisocabtagene maraleucel as a second-line treatment | Interim results of phase II PILOT trial

The ongoing, open-label phase II PILOT trial (NCT03483103) is the first study to assess the efficacy and...

Jul 22, 2020

| ASCO 2020

EMA validates marketing authorization application for lisocabtagene maraleucel for the treatment of adults with B-cell non-Hodgkin lymphoma

On July 17, 2020, the European Medicines Agency (EMA)...

Jul 21, 2020

Most Viewed

Prof. Gilles Salles | EBMT 2018 | Emerging CAR T-cell therapy in Lymphoma

Alexander study: CD19/22 dual targeting CAR T-cell therapy with pembrolizumab in R/R DLBCL

An update in CLL from EHA 2020

Practice-changing abstracts in indolent lymphoma at EHA 2020

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

A retrospective study of the clinical and pathological features of peripheral T-cell lymphomas in a Spanish population

Aug 11, 2020

| PTCL

Aug 7, 2020

| FL

Aug 4, 2020

| FL

Aug 4, 2020

| DLBCL

Gilles Salles

Diffuse large B-cell lymphoma

Aug 4, 2020

| DLBCL

Jul 31, 2020

| ASCO 2020

Jul 22, 2020

| ASCO 2020

Jul 21, 2020

Mature T and NK cell neoplasms

Aug 11, 2020

| PTCL

Jul 24, 2020

| CTCL

Jul 24, 2020

| CTCL

Jul 13, 2020

| ALCL

Most Read

Follicular lymphoma

Aug 7, 2020

| FL

Aug 4, 2020

| FL

Jul 22, 2020

| ASCO 2020

Jul 21, 2020

Most Viewed